Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-06-14, Stock:ABBV, The news for the past five days is as follows:
2021-06-07: NEWS1: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS2: AbbVie's Ibrutinib/Venetoclax Combo Potentially Chemo-free, Fixed-Duration Treatment Option in Leukemia.NEWS3: CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL).NEWS4: Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis.
2021-06-08: NEWS1: Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign.NEWS2: AbbVie Inc. (NYSE:ABBV) Delivered A Better ROE Than Its Industry.
2021-06-09: NEWS1: 2 High-Yield Dividend Stocks for 2021.NEWS2: AbbVie, Caraway Therapeutics Team Up To Develop TMEM175 Modulators For Parkinson's Disease.
2021-06-10: NEWS1: 2 Top Healthcare Stocks to Buy in a Market Crash.
2021-06-11: NEWS1: AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment.NEWS2: 3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market.NEWS3: New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment.

Answer: Decrease